Irritable Bowel Syndrome Treatment Market Overview
Irritable bowel syndrome treatment market was valued at USD 3.60 Billion in 2021, registering a CAGR of 8.7% during the forecast period (2022-2030), and is projected to be worth USD 7.63 Billion by 2030. One of the most prevalent functional gastrointestinal illnesses, irritable bowel syndrome is thought to affect between 10-15% of people worldwide. IBS is thought to impact between 25 and 45 million people in the United States, according to the International Foundation for Gastrointestinal Disorders (IFFGD), a research organization. IBS sufferers tend to be female in two out of three cases, and the majority are under 50. Irritable bowel syndrome signs account for 20–40% of all patient visits to gastroenterologists. However, many people are still uninformed and go untreated even though their symptoms point to a recognized medical condition. Numerous awareness initiatives are being undertaken as a result to spread knowledge about the illness.
For instance, the IBS Network in the U.K. organized several events throughout April 2018 to reduce the stigma associated with the condition. The campaign was aimed at IBS sufferers as well as doctors who treat patients with the condition. These activities and campaigns are intended to increase understanding of the problem and motivate sufferers to get treatment for their ailments. The market for IBS treatments is then anticipated to increase more quickly as a result.
Irritable Bowel Syndrome Treatment Market Dynamics:
Irritable Bowel Syndrome (IBS) treatment focuses on symptom relief to help you live as symptom-free life as possible. Stress management, dietary and lifestyle adjustments, as well as stress management techniques, can frequently reduce mild symptoms. Try to avoid eating things that make your symptoms worse.
Driver:
The market is being driven by rising rates of the target condition and rising treatment usage for it. Increased usage of anti-diarrheal medications and alosetron, two types of irritable bowel syndrome treatment pharmaceuticals, as alternatives to traditional therapeutic approaches, has improved the management of the condition and, these factors are driving the growth of the market.
Restraint:
Current societal and economic issues are limiting the expansion of the irritable bowel syndrome therapy market. Irritable bowel syndrome is more common in developing countries, and there is a dearth of knowledge about the symptoms that can cause it, which has hampered business growth. Additionally, the internalized stigma of lacking medical attention for irritable bowel syndrome due to perceived embarrassment or humiliation has resulted in the under-diagnosis of IBS, which is detrimental to the health and well-being of patients.
Opportunities
During the projection period, the growth is anticipated to increase due to the increasing commercialization of current goods in various countries. Linzess’s growing popularity in the U.S., Europe, and Japan has greatly aided in revenue development. In January 2019, Linzess received approval in China, which is anticipated to substantially grow during the forecast period and create profitable opportunities for the market.
Irritable Bowel Syndrome Treatment Market Report Cover:
| Report Attributes | Report Details |
| Study Timeline | 2016-2030 |
| Market Size in 2030 (USD Billion) | 7.63 Billion |
| CAGR (2022-2030) | 8.7% |
| By Type | IBS-C, IBS-D |
| By Product | XifaxanLinzess/Constella, Viberzi, Amitiza, Others |
| By geography | North America– (U.S., Canada, Mexico)
Europe- (Germany, France, U.K., Russia, Italy, Spain, BENELUX, Rest of Europe) Asia Pacific- (China, Japan, India, South Korea, Australia, ASEAN, Rest of Asia Pacific) Latin America- (Brazil, Argentina, Chile, Rest of Latin America) The Middle East and Africa- (GCC, Turkey, Israel, Rest of MEA) |
| Key Players | Ironwood Pharmaceuticals, Inc.; Allergan; Astellas Pharma, Inc.; Takeda Pharmaceutical Company Limited AstraZeneca; Sebela Pharmaceuticals Inc.; Synergy Pharmaceuticals In. Bausch Health; Synthetic Biologics, Inc.; and Ardelyx. |
Irritable Bowel Syndrome Treatment Market Segment Analysis:
By Type
By type segment, the irritable bowel syndrome treatment market is divided into diarrhea-predominant (IBS-D) and constipation-predominant segments (IBS-C). Due to reasons including rising prevalence and increased use of medications such as Linzess/Constella and Amitiza, IBS-C generated the most revenue in 2021. The sector is also anticipated to increase at the quickest rate in the market for treating irritable bowel syndrome (IBS) over the forecast period as a result of the anticipated release of promising medications like SYN-010 and Tenapanor, which are currently undergoing clinical trials. AstraZeneca, Ironwood, Astellas, and Allergan are a few of the top companies engaged in this market and are expected to boom the growth of the irritable bowel syndrome treatment market.
By Product
Xifaxan, Linzess/Constella, Viberzi, and Amitiza are some of the top medications produced to treat irritable bowel syndrome (IBS) symptoms. According to estimates, Linzess/Constella (Linaclotide) generated the most revenue in 2020 due to the product’s increasing popularity in important markets such as the United States, the United Kingdom, Germany, Spain, Italy, and Japan. Additionally, Linzess experienced a notable growth rate in Japan in 2020. Further, it is predicted that during the projected period, the Linzess/Constella segment is also expected to increase at the fastest rate. Further, Ironwood and Allergan commercialize linaclotide in the US. under the brand names Linzess and Constella, respectively. The sole rights to create and market linaclotide as Linzess in China and Japan, respectively, are held by Astellas and AstraZeneca. Hence, the product segment is expected to grab significant market attention during the forecast period.
By Region
North America generated the greatest revenue in 2021 and is anticipated to continue the lead during the projected period. Due to the existence of major market participants, a developed healthcare infrastructure, increased patient awareness, and a significant presence of novel goods, the area held the lion’s share of the market. Additionally, A huge target population and the increasing commercialization of IBS products in the region are expected to drive the European market with the quickest growth throughout the projected period. In addition, stepping up efforts to increase awareness of the illness in the area is anticipated to speed up market expansion.
Irritable Bowel Syndrome Treatment Market Competitive Landscape:
The competitive landscape of the market has been analyzed in the report, along with the detailed profiles of the major players operating in the industry. The majority of manufacturers are concentrating on new Type launches, improvements to current Types, and mergers and acquisitions. –
- Ironwood Pharmaceuticals, Inc
- Allergan
- Astellas Pharma, Inc.
- Takeda Pharmaceutical Company Limited AstraZeneca
- Sebela Pharmaceuticals Inc.
- Synergy Pharmaceuticals In. Bausch Health
- Synthetic Biologics, Inc.
- Ardelyx.
Table of Content
- Introduction
- Market Introduction
- Market Research Methodology
- Research Process
- Primary Research
- Secondary Research
- Data Collection Technique
- Data Sources
- Market Estimation Methodology
- Limitations of the Study
- Type Picture of Irritable Bowel Syndrome Treatment
- Global Irritable Bowel Syndrome Treatment Market: Classification
- Geographic Scope
- Years Considered for the Study
- Research Methodology in brief
- Parent Market Overview
- Overall Irritable Bowel Syndrome Treatment Market Regional Demand
- Research Programs/Design
- Market Breakdown and Data Triangulation Approach
- Data Source
- Secondary Sources
- Primary Sources
- Primary Interviews
- Average Type primary breakdown ratio
- Market Dynamics
- Drivers
- Drivers
- Restraints
- Restraints
- Opportunity
- Impact forces on market dynamics
- Impact forces during the forecast years
- Industry Value Chain
- Upstream analysis
- Downstream analysis
- Therapeutic
- Direct Channel
- Indirect Channel
- Potential Customers
- Manufacturing/Operational Cost Analysis
- Pricing Analysis by Region
- Key Type Landscape
- Regulatory Analysis
- Porter’s Analysis
- Supplier Power
- Buyer Power
- Substitution Threat
- Threat from New Entry
- Competitive Rivalry
- PESTEL Analysis
- Political Factors
- Economic Factor
- Social Factors
- Technological Factor
- Environmental Factors
- Legal Factor
- Covid-19 impact on Global Economy
- Covid-19 impact on Irritable Bowel Syndrome Treatment Market demand
- Post-Covid Impact on Irritable Bowel Syndrome Treatment Market Demand
- Impact Analysis of Russia-Ukraine Conflict
- Drivers
- Global Irritable Bowel Syndrome Treatment Market Segmentation, Revenue (USD Billion), (2022-2030)
- By Type
- IBS-C
- Linzess/Constella
- Amitiza
- Others
- IBS-D
- Xifaxan
- Viberzi
- Others
- By Product
- Xifaxan
- Linzess/Constella
- Viberzi
- Amitiza
- Others
- IBS-C
- By Type
- By Global Irritable Bowel Syndrome Treatment Market Overview, By Region
- North America Irritable Bowel Syndrome Treatment Market Revenue (USD Billion), by Countries, (2022-2030)
- US
- By Type
- By Product
- Canada
- Mexico
- US
- Europe Irritable Bowel Syndrome Treatment Market Revenue (USD Billion), by Countries, (2022-2030)
- France
- UK
- Spain
- Russia
- Italy
- BENELUX
- Asia Pacific Irritable Bowel Syndrome Treatment Market Revenue (USD Billion), by Countries, (2022-2030)
- China
- Japan
- Australia
- South Korea
- India
- ASEAN
- North America Irritable Bowel Syndrome Treatment Market Revenue (USD Billion), by Countries, (2022-2030)
- Latin America Irritable Bowel Syndrome Treatment Market Revenue (USD Billion), by Countries, (2022-2030)
- Brazil
- Argentina
- Chile
- The Middle East and Africa Irritable Bowel Syndrome Treatment Market Revenue (USD Billion), by Countries, (2022-2030)
- GCC
- Turkey
- South Africa
- Global Irritable Bowel Syndrome Treatment Market Revenue: Competitive Analysis, 2021
- Key strategies by players
- Revenue (USD Billion and %), By manufacturers, 2021
- Player Positioning by Market Players, 2021
- Competitive Analysis
- Baxter International Inc.
- Business Overview
- Business Financials (USD Billion)
- Type Category, Source, and Specification
- Main Business/Business Overview
- Geographical Analysis
- Recent Development
- Swot Analysis
- Bio Type laboratory
- Biotest AG
- CSL Ltd.
- Grifols SA
- Kedrion S.P.A (Kedrion Biopharma Inc.)
- LFB S. A.
- Octapharma AG
- Sanquin Blood Supply Foundation
- Takeda Pharmaceutical Company Limited
- Baxter International Inc.
- Market Research Findings & Conclusion
Disclaimer
Research Methodology
The Market Research Community offers numerous solutions and its full addition in the research methods to be skilled at each step. We use wide-ranging resources to produce the best outcome for our customers. The achievement of a research development is completely reliant on the research methods implemented by the company. We always faithful to our clients to find opportunities by examining the global market and offering economic insights.Market Research Community are proud of our widespread coverage that encompasses the understanding of numerous major industry domains. Company offers consistency in our research report, we also offers on the part of the analysis of forecast across a range of coverage geographies and coverage. The research teams carry out primary and secondary research to carry out and design the data collection methods.